The highest frequency of FDX1 alterations (>3%) was observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), followed by nonseminomatous testicular tumor (NSGCT) and seminoma (SEMI) (Figure 2A). This evidence concerns the gene FDX1 and endocervical adenocarcinoma.